Is STTK or HUMA more profitable?

Shattuck Labs has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Shattuck Labs' return on equity of -43.57% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Humacyte -4,556.29% -983.32% -88.84%

Does the media refer more to STTK or HUMA?

In the previous week, Shattuck Labs had 2 more articles in the media than Humacyte. MarketBeat recorded 5 mentions for Shattuck Labs and 3 mentions for Humacyte. Shattuck Labs' average media sentiment score of 1.41 beat Humacyte's score of 0.94 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HUMA or BBOT?

In the previous week, BridgeBio Oncology Therapeutics had 17 more articles in the media than Humacyte. MarketBeat recorded 20 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Humacyte. Humacyte's average media sentiment score of 0.94 beat BridgeBio Oncology Therapeutics' score of 0.09 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Oncology Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CTMX or HUMA?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Humacyte. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Humacyte. CytomX Therapeutics' average media sentiment score of 1.45 beat Humacyte's score of 0.94 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALLO or HUMA?

In the previous week, Allogene Therapeutics had 4 more articles in the media than Humacyte. MarketBeat recorded 7 mentions for Allogene Therapeutics and 3 mentions for Humacyte. Humacyte's average media sentiment score of 0.94 beat Allogene Therapeutics' score of 0.55 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HUMA or TECX?

In the previous week, Humacyte and Humacyte both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 1.03 beat Humacyte's score of 0.94 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Humacyte (HUMA) Competitors

$0.57 +0.00 (+0.09%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.57 +0.00 (+0.25%)

As of 09/11/2026 07:49 PM Eastern

Compare

HUMA vs. STTK, BBOT, CTMX, ALLO, and TECX

Should you buy Humacyte stock or one of its competitors? Humacyte's main competitors and comparable companies include Shattuck Labs (STTK), BridgeBio Oncology Therapeutics (BBOT), CytomX Therapeutics (CTMX), Allogene Therapeutics (ALLO), and Tectonic Therapeutic (TECX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Humacyte compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 3.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Shattuck Labs presently has a consensus target price of $12.78, suggesting a potential upside of 106.09%. Humacyte has a consensus target price of $6.54, suggesting a potential upside of 1,052.51%. Given Humacyte's higher possible upside, analysts clearly believe Humacyte is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Shattuck Labs has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Shattuck Labs' return on equity of -43.57% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Humacyte	-4,556.29%	-983.32%	-88.84%

Shattuck Labs has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

In the previous week, Shattuck Labs had 2 more articles in the media than Humacyte. MarketBeat recorded 5 mentions for Shattuck Labs and 3 mentions for Humacyte. Shattuck Labs' average media sentiment score of 1.41 beat Humacyte's score of 0.94 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Humacyte has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	622.23	-$48.81M	-$0.51	N/A
Humacyte	$2.04M	77.29	-$40.83M	-$0.49	N/A

Summary

Shattuck Labs beats Humacyte on 11 of the 17 factors compared between the two stocks.

How does Humacyte compare to BridgeBio Oncology Therapeutics?

Humacyte (NASDAQ:HUMA) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Humacyte has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	77.29	-$40.83M	-$0.49	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

Humacyte currently has a consensus target price of $6.54, indicating a potential upside of 1,052.51%. BridgeBio Oncology Therapeutics has a consensus target price of $22.88, indicating a potential upside of 362.12%. Given Humacyte's higher possible upside, analysts clearly believe Humacyte is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, BridgeBio Oncology Therapeutics had 17 more articles in the media than Humacyte. MarketBeat recorded 20 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Humacyte. Humacyte's average media sentiment score of 0.94 beat BridgeBio Oncology Therapeutics' score of 0.09 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Humacyte has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

44.7% of Humacyte shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BridgeBio Oncology Therapeutics beats Humacyte on 8 of the 15 factors compared between the two stocks.

How does Humacyte compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

CytomX Therapeutics currently has a consensus price target of $11.90, suggesting a potential upside of 261.70%. Humacyte has a consensus price target of $6.54, suggesting a potential upside of 1,052.51%. Given Humacyte's higher possible upside, analysts clearly believe Humacyte is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

CytomX Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Humacyte. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.41	-$17.37M	-$0.50	N/A
Humacyte	$2.04M	77.29	-$40.83M	-$0.49	N/A

CytomX Therapeutics has a net margin of -435.21% compared to Humacyte's net margin of -4,556.29%. CytomX Therapeutics' return on equity of -38.46% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Humacyte	-4,556.29%	-983.32%	-88.84%

In the previous week, CytomX Therapeutics had 1 more articles in the media than Humacyte. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Humacyte. CytomX Therapeutics' average media sentiment score of 1.45 beat Humacyte's score of 0.94 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CytomX Therapeutics beats Humacyte on 12 of the 17 factors compared between the two stocks.

How does Humacyte compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

In the previous week, Allogene Therapeutics had 4 more articles in the media than Humacyte. MarketBeat recorded 7 mentions for Allogene Therapeutics and 3 mentions for Humacyte. Humacyte's average media sentiment score of 0.94 beat Allogene Therapeutics' score of 0.55 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Humacyte has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	30,748.61	-$190.89M	-$0.67	N/A
Humacyte	$2.04M	77.29	-$40.83M	-$0.49	N/A

Allogene Therapeutics presently has a consensus price target of $8.30, suggesting a potential upside of 366.29%. Humacyte has a consensus price target of $6.54, suggesting a potential upside of 1,052.51%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Allogene Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Allogene Therapeutics' return on equity of -50.04% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Humacyte	-4,556.29%	-983.32%	-88.84%

Summary

Allogene Therapeutics beats Humacyte on 9 of the 17 factors compared between the two stocks.

How does Humacyte compare to Tectonic Therapeutic?

Humacyte (NASDAQ:HUMA) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Tectonic Therapeutic has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Tectonic Therapeutic's return on equity of -35.26% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Humacyte presently has a consensus price target of $6.54, indicating a potential upside of 1,052.51%. Tectonic Therapeutic has a consensus price target of $77.25, indicating a potential upside of 165.92%. Given Humacyte's higher probable upside, equities research analysts clearly believe Humacyte is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

44.7% of Humacyte shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Humacyte has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	77.29	-$40.83M	-$0.49	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

In the previous week, Humacyte and Humacyte both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 1.03 beat Humacyte's score of 0.94 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Humacyte has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market.

Summary

Tectonic Therapeutic beats Humacyte on 9 of the 15 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$157.68M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.72%
P/E Ratio	-1.16	14.18	274.94	25.36
Price / Sales	77.29	1,374.96	685.43	116.41
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	28.38	15.12	10.33	6.20
Net Income	-$40.83M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-6.17%	-4.34%	-3.32%	-2.35%
1 Month Performance	3.20%	0.54%	-0.53%	-3.23%
1 Year Performance	-61.39%	40.74%	23.51%	8.79%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	3.1925 of 5 stars	$0.57 +0.1%	$6.54 +1,052.5%	-61.4%	$157.68M	$2.04M	N/A	150
STTK Shattuck Labs	3.7688 of 5 stars	$7.01 -0.4%	$12.78 +82.3%	+222.9%	$706.56M	$1M	N/A	100	Positive News
BBOT BridgeBio Oncology Therapeutics	3.0081 of 5 stars	$8.80 +0.7%	$24.40 +177.3%	N/A	$700.72M	N/A	N/A	N/A	Trending News Analyst Forecast
CTMX CytomX Therapeutics	2.8917 of 5 stars	$3.36 +4.7%	$11.90 +254.2%	+64.5%	$699.46M	$76.20M	N/A	170	Positive News Gap Down
ALLO Allogene Therapeutics	1.9485 of 5 stars	$2.00 -1.0%	$8.30 +315.0%	+57.5%	$697.89M	$20K	N/A	310	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. STTK, BBOT, CTMX, ALLO, and TECX

How does Humacyte compare to Shattuck Labs?

Summary

How does Humacyte compare to BridgeBio Oncology Therapeutics?

Summary

How does Humacyte compare to CytomX Therapeutics?

Summary

How does Humacyte compare to Allogene Therapeutics?

Summary

How does Humacyte compare to Tectonic Therapeutic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. STTK, BBOT, CTMX, ALLO, and TECX

How does Humacyte compare to Shattuck Labs?

Do institutionals and insiders have more ownership in STTK or HUMA?

Do analysts rate STTK or HUMA?

Is STTK or HUMA more profitable?

Which has more risk and volatility, STTK or HUMA?

Does the media refer more to STTK or HUMA?

Which has better valuation and earnings, STTK or HUMA?

Summary

How does Humacyte compare to BridgeBio Oncology Therapeutics?

Which has better valuation & earnings, HUMA or BBOT?

Do analysts prefer HUMA or BBOT?

Does the media prefer HUMA or BBOT?

Which has more risk and volatility, HUMA or BBOT?

Is HUMA or BBOT more profitable?

Do insiders and institutionals have more ownership in HUMA or BBOT?

Summary

How does Humacyte compare to CytomX Therapeutics?

Do analysts rate CTMX or HUMA?

Which has more volatility & risk, CTMX or HUMA?

Which has higher earnings & valuation, CTMX or HUMA?

Is CTMX or HUMA more profitable?

Does the media favor CTMX or HUMA?

Do institutionals and insiders hold more shares of CTMX or HUMA?

Summary

How does Humacyte compare to Allogene Therapeutics?

Does the media favor ALLO or HUMA?

Which has more volatility & risk, ALLO or HUMA?

Do institutionals and insiders hold more shares of ALLO or HUMA?

Which has preferable valuation & earnings, ALLO or HUMA?

Do analysts prefer ALLO or HUMA?

Is ALLO or HUMA more profitable?

Summary

How does Humacyte compare to Tectonic Therapeutic?

Is HUMA or TECX more profitable?

Do analysts recommend HUMA or TECX?

Do insiders and institutionals have more ownership in HUMA or TECX?

Which has stronger valuation & earnings, HUMA or TECX?

Does the media refer more to HUMA or TECX?

Which has more volatility and risk, HUMA or TECX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools